FINAL FIVE-YEAR FOLLOW-UP OF POLYMER-FREE SIROLIMUS- AND PROBUCOL-ELUTING STENTS VERSUS NEW GENERATION ZOTAROLIMUS-ELUTING STENTS IN PATIENTS WITH CORONARY ARTERY DISEASE  by Byrne, Robert A. et al.
TCT@ACC-i2: Interventional Cardiology
A1688
JACC March 17, 2015
Volume 65, Issue 10S
Final Five-year Follow-Up oF polymer-Free sirolimUs- and probUCol-elUtinG stents 
versUs new Generation ZotarolimUs-elUtinG stents in patients with Coronary 
artery disease
Moderated Poster Contributions
TCT@ACC-i2 Moderated Poster Theater, Poster Hall B1
Saturday, March 14, 2015, 11:00 a.m.-11:10 a.m.
Session Title: TCT@ACC-i2: Interventional Cardiology I
Abstract Category: 34. TCT@ACC-i2: Coronary Intervention: Devices
Presentation Number: 2105M-11
Authors: Robert A. Byrne, Sebastian Kufner, Jonas Sorges, Janika Repp, Salvatore Cassese, Stefanie Schulz, Massimiliano Fusaro, Ilka 
Ott, Tareq Ibrahim, Karl-Ludwig Laugwitz, Adnan Kastrati, Deutsches Herzzentrum, Munich, Germany, Med. Klinik, Klinikum Rechts der 
Isar, Munich, Germany
background: ISAR-TEST 5 was a large-scale randomized trial which demonstrated the non-inferiority of a polymer-free dual-drug 
sirolimus- and probucol-eluting stent compared to a new generation durable polymer zotarolimus-eluting stent (ZES) in 3002 randomized 
patients at 1-year follow-up. Long-term follow-up is required to investigate the hypothesized late performance advantage of polymer-free 
DES. The aim of the present analysis was to evaluate clinical outcomes at 5 years.
methods: A total of 3002 patients undergoing percutaneous coronary intervention were randomly assigned to treatment with a polymer-
free sirolimus- and probucol-eluting stent (backbone Translumina, Hechingen, Germany; n=2002) versus a ZES stent (Endeavor Resolute, 
Medtronic Vascular, Santa Rosa, Ca.; n=1000). There were minimal exclusion criteria. Clinical follow-up was performed to 5 years post 
enrolment. The primary endpoint was the combined incidence of cardiac death, target-vessel-related myocardial infarction (MI) or target 
lesion revascularization at 2 years. Secondary endpoints comprised the composite of death or any MI, target lesion revascularization 
and probable or definite stent thrombosis. The primary endpoint will also be evaluated in pre-defined sub-groups according to sex, age, 
reference vessel diameter and diabetes.
results: The results of final 5-year follow-up will be available for presentation at ACC 2015.
Conclusion:  ISAR-TEST 5 is the largest trial to date examining outcomes of patient treated with polymer-free drug-eluting stents. Final 
5-year follow-up from this clinical trial will provide important insights into the late performance characteristics of both sirolimus- and 
probucol-eluting stents and new generation durable polymer ZES. In addition the availability of long-term data from large numbers of 
treated patients will permit examination of the potential late performance advantage of polymer-free stent coatings.
